Eli Lilly Showcases New Therapy Data at ASCO Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 41 minutes ago
0mins
Source: PRnewswire
- Clinical Trial Results: Eli Lilly's Phase 3 LIBRETTO-432 study demonstrates significant event-free survival outcomes for Retevmo (selpercatinib) in RET fusion-positive NSCLC patients, likely enhancing the drug's market acceptance and sales growth.
- New Drug Presentation: Verzenio (abemaciclib) has been selected for a Plenary Session presentation in the Phase 3 SARC041 study for patients with advanced dedifferentiated liposarcoma, indicating Lilly's ongoing innovation and exploration of new indications in cancer treatment.
- Acquisition Progress: Lilly has agreed to acquire Kelonia Therapeutics, which will present updated data on its BCMA-targeted CAR-T therapy for relapsed multiple myeloma at the conference, further strengthening Lilly's competitive position in cell therapy.
- Diverse Investments: Lilly will also showcase initial clinical results for an investigational ADC targeting Nectin-4, highlighting its potential in treating various cancers and reflecting the company's broad investment and commitment to oncology research and development.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1018.870
Low
950.00
Averages
1192
High
1500
Current: 1018.870
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Eli Lilly Showcases New Therapy Data at ASCO Meeting
- Clinical Trial Results: Eli Lilly's Phase 3 LIBRETTO-432 study demonstrates significant event-free survival outcomes for Retevmo (selpercatinib) in RET fusion-positive NSCLC patients, likely enhancing the drug's market acceptance and sales growth.
- New Drug Presentation: Verzenio (abemaciclib) has been selected for a Plenary Session presentation in the Phase 3 SARC041 study for patients with advanced dedifferentiated liposarcoma, indicating Lilly's ongoing innovation and exploration of new indications in cancer treatment.
- Acquisition Progress: Lilly has agreed to acquire Kelonia Therapeutics, which will present updated data on its BCMA-targeted CAR-T therapy for relapsed multiple myeloma at the conference, further strengthening Lilly's competitive position in cell therapy.
- Diverse Investments: Lilly will also showcase initial clinical results for an investigational ADC targeting Nectin-4, highlighting its potential in treating various cancers and reflecting the company's broad investment and commitment to oncology research and development.
See More
Eli Lilly's Obesity Therapy Trial Shows Significant Results
- Significant Weight Loss: Eli Lilly's next-gen obesity therapy retatrutide achieved an average weight loss of up to 28% over 80 weeks in trials, indicating strong potential in the obesity treatment market, which could significantly enhance the company's competitive edge.
- Competitive Comparison: The therapy's efficacy surpasses Lilly's own tirzepatide and Novo Nordisk's semaglutide, highlighting its leading position in the emerging obesity treatment market and potentially attracting more patients to choose this product.
- Safety and Tolerability: Although 11% of patients discontinued treatment at the highest 12 mg dose due to adverse events, the overall tolerability profile is consistent with other gut-hormone-based therapies, which may improve patient acceptance upon future commercialization.
- Analyst Optimism: BMO Capital Markets analysts noted the significantly improved discontinuation rate of retatrutide, likely boosting its market acceptance, while Citi analysts praised the data showing a 30% average weight loss in severely obese patients at the highest dose, describing it as unprecedented efficacy.
See More
Market Trends and Company Earnings Insights
- Oil and Treasury Yields: U.S. benchmark WTI crude prices have surged back above $100 per barrel, with the 10-year Treasury yield hovering around 4.6%, leading to lower stock futures this morning, reflecting market concerns over inflation and rising interest rates that could dampen investor confidence.
- Nvidia Buyback Plan: Nvidia has added $80 billion to its stock buyback authorization, on top of the existing $39 billion, and increased its annual dividend payout from $0.04 to $1, indicating a strong commitment to shareholder returns, although the market reaction has been muted, this could bolster investor confidence in the long run.
- Walmart's Earnings Outlook: Walmart is feeling the pinch from high gas prices, resulting in a disappointing earnings outlook despite matching earnings and beating revenue expectations in Q1, with shares down approximately 2.5%, reflecting cautious sentiment regarding future growth prospects.
- Inflation Rollback: Kroger CEO Greg Foran announced plans for the largest price cuts in years to stay competitive, although shares fell about 4% following the news, this strategic move could enhance market share and customer loyalty over time.
See More
Eli Lilly's Retatrutide Trial Achieves Key Weight Loss Goals
- Significant Weight Loss: In the TRIUMPH-1 trial, all doses of retatrutide met primary and secondary endpoints, with users on the highest dose losing an average of over 28% of body weight, and over 45% achieving a loss of 30% or more, comparable to results typically seen after bariatric surgery.
- Cardiovascular Improvements: The drug demonstrated notable improvements in multiple cardiometabolic markers, including cholesterol, blood pressure, inflammation, and waist size, further validating its potential in obesity treatment.
- Market Competitive Edge: Eli Lilly is strengthening its obesity drug pipeline with retatrutide, which is expected to be a major driver in maintaining its lead in the rapidly growing weight-loss market, particularly amid competition with Novo Nordisk.
- Monitoring Side Effects: Despite the significant efficacy, about 11% of participants on the 12 mg dose dropped out of the trial, with 13% reporting dysesthesia and over 8% experiencing urinary tract infections, indicating the need for careful monitoring of patient safety during rollout.
See More
Viking Therapeutics: A Potential New Star in Weight Loss Drugs
- Market Share Shift: Eli Lilly currently holds a 60% share of the U.S. GLP-1 weight loss drug market, and while Novo Nordisk remains a giant, Lilly's success indicates increasing competitive pressure from new entrants.
- Clinical Trial Progress: Viking Therapeutics' VK2735 is undergoing phase 3 trials, with the oral version set to enter phase 3 in Q4, potentially providing the company with an opportunity to compete against Lilly.
- Weight Loss Market Outlook: Analysts forecast the weight loss drug market to approach $100 billion by 2030, and Viking's dual GLP-1/GIP offering stands out, potentially attracting more attention from patients and doctors.
- Competitive Challenges: Although Viking's clinical results are comparable to those of Lilly and Novo, achieving market success will require overcoming challenges such as Lilly's brand trust and manufacturing capabilities.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. GLP-1 weight loss drug market, showcasing its competitive strength despite Novo Nordisk's long-standing presence since 2017.
- Significant Revenue Growth: Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, generated over $12 billion in revenue in the latest quarter, indicating robust demand and profitability for its weight loss products.
- Viking's Potential: Viking Therapeutics is conducting phase 3 trials for VK2735, which demonstrated over 14% weight reduction in phase 2 trials, positioning it as a potential competitor to market leader Eli Lilly if approved.
- Expansive Market Outlook: Analysts forecast the weight loss drug market to reach nearly $100 billion by 2030, with Viking's unique dual GLP-1/GIP formulation potentially attracting significant interest from patients and doctors alike.
See More
Eli Lilly Showcases New Therapy Data at ASCO Meeting
- Clinical Trial Results: Eli Lilly's Phase 3 LIBRETTO-432 study demonstrates significant event-free survival outcomes for Retevmo (selpercatinib) in RET fusion-positive NSCLC patients, likely enhancing the drug's market acceptance and sales growth.
- New Drug Presentation: Verzenio (abemaciclib) has been selected for a Plenary Session presentation in the Phase 3 SARC041 study for patients with advanced dedifferentiated liposarcoma, indicating Lilly's ongoing innovation and exploration of new indications in cancer treatment.
- Acquisition Progress: Lilly has agreed to acquire Kelonia Therapeutics, which will present updated data on its BCMA-targeted CAR-T therapy for relapsed multiple myeloma at the conference, further strengthening Lilly's competitive position in cell therapy.
- Diverse Investments: Lilly will also showcase initial clinical results for an investigational ADC targeting Nectin-4, highlighting its potential in treating various cancers and reflecting the company's broad investment and commitment to oncology research and development.
See More
Eli Lilly's Obesity Therapy Trial Shows Significant Results
- Significant Weight Loss: Eli Lilly's next-gen obesity therapy retatrutide achieved an average weight loss of up to 28% over 80 weeks in trials, indicating strong potential in the obesity treatment market, which could significantly enhance the company's competitive edge.
- Competitive Comparison: The therapy's efficacy surpasses Lilly's own tirzepatide and Novo Nordisk's semaglutide, highlighting its leading position in the emerging obesity treatment market and potentially attracting more patients to choose this product.
- Safety and Tolerability: Although 11% of patients discontinued treatment at the highest 12 mg dose due to adverse events, the overall tolerability profile is consistent with other gut-hormone-based therapies, which may improve patient acceptance upon future commercialization.
- Analyst Optimism: BMO Capital Markets analysts noted the significantly improved discontinuation rate of retatrutide, likely boosting its market acceptance, while Citi analysts praised the data showing a 30% average weight loss in severely obese patients at the highest dose, describing it as unprecedented efficacy.
See More
Market Trends and Company Earnings Insights
- Oil and Treasury Yields: U.S. benchmark WTI crude prices have surged back above $100 per barrel, with the 10-year Treasury yield hovering around 4.6%, leading to lower stock futures this morning, reflecting market concerns over inflation and rising interest rates that could dampen investor confidence.
- Nvidia Buyback Plan: Nvidia has added $80 billion to its stock buyback authorization, on top of the existing $39 billion, and increased its annual dividend payout from $0.04 to $1, indicating a strong commitment to shareholder returns, although the market reaction has been muted, this could bolster investor confidence in the long run.
- Walmart's Earnings Outlook: Walmart is feeling the pinch from high gas prices, resulting in a disappointing earnings outlook despite matching earnings and beating revenue expectations in Q1, with shares down approximately 2.5%, reflecting cautious sentiment regarding future growth prospects.
- Inflation Rollback: Kroger CEO Greg Foran announced plans for the largest price cuts in years to stay competitive, although shares fell about 4% following the news, this strategic move could enhance market share and customer loyalty over time.
See More
Eli Lilly's Retatrutide Trial Achieves Key Weight Loss Goals
- Significant Weight Loss: In the TRIUMPH-1 trial, all doses of retatrutide met primary and secondary endpoints, with users on the highest dose losing an average of over 28% of body weight, and over 45% achieving a loss of 30% or more, comparable to results typically seen after bariatric surgery.
- Cardiovascular Improvements: The drug demonstrated notable improvements in multiple cardiometabolic markers, including cholesterol, blood pressure, inflammation, and waist size, further validating its potential in obesity treatment.
- Market Competitive Edge: Eli Lilly is strengthening its obesity drug pipeline with retatrutide, which is expected to be a major driver in maintaining its lead in the rapidly growing weight-loss market, particularly amid competition with Novo Nordisk.
- Monitoring Side Effects: Despite the significant efficacy, about 11% of participants on the 12 mg dose dropped out of the trial, with 13% reporting dysesthesia and over 8% experiencing urinary tract infections, indicating the need for careful monitoring of patient safety during rollout.
See More
Viking Therapeutics: A Potential New Star in Weight Loss Drugs
- Market Share Shift: Eli Lilly currently holds a 60% share of the U.S. GLP-1 weight loss drug market, and while Novo Nordisk remains a giant, Lilly's success indicates increasing competitive pressure from new entrants.
- Clinical Trial Progress: Viking Therapeutics' VK2735 is undergoing phase 3 trials, with the oral version set to enter phase 3 in Q4, potentially providing the company with an opportunity to compete against Lilly.
- Weight Loss Market Outlook: Analysts forecast the weight loss drug market to approach $100 billion by 2030, and Viking's dual GLP-1/GIP offering stands out, potentially attracting more attention from patients and doctors.
- Competitive Challenges: Although Viking's clinical results are comparable to those of Lilly and Novo, achieving market success will require overcoming challenges such as Lilly's brand trust and manufacturing capabilities.
See More
Eli Lilly's Dominance in Weight Loss Drug Market
- Market Share Leadership: Eli Lilly commands a 60% share of the U.S. GLP-1 weight loss drug market, showcasing its competitive strength despite Novo Nordisk's long-standing presence since 2017.
- Significant Revenue Growth: Eli Lilly's tirzepatide, marketed as Mounjaro and Zepbound, generated over $12 billion in revenue in the latest quarter, indicating robust demand and profitability for its weight loss products.
- Viking's Potential: Viking Therapeutics is conducting phase 3 trials for VK2735, which demonstrated over 14% weight reduction in phase 2 trials, positioning it as a potential competitor to market leader Eli Lilly if approved.
- Expansive Market Outlook: Analysts forecast the weight loss drug market to reach nearly $100 billion by 2030, with Viking's unique dual GLP-1/GIP formulation potentially attracting significant interest from patients and doctors alike.
See More
